At Pharmidex, we help drug developers hit their IND submission dates with high-quality, efficient solutions
September 1, 2025
- Designing robust preclinical studies that deliver accurate data the first time.
- Building flexibility into plans to prevent delays when priorities shift.
- Coordinating ADME, PK/PD, and toxicology in parallel to save weeks.
With over 16,000 projects conducted successfully, work with a proven partner from early discovery to regulatory submission.
Our tailored, quality-driven approach keeps your programme on track and your milestones within reach.
Let’s make your IND deadline a milestone you hit with confidence
We’re proud to announce that Pharmidex has joined the Good Clinical Practice (GCP) Network , a global collaboration advancing ICH-GCP excellence in clinical research. For us, quality and data integrity are not box-ticking exercises, they are fundamental to credible science and responsible drug development. From pre-clinical research through to clinical delivery, we are committed to: • Regulatory rigour • Ethical conduct • Participant protection • Scientifically robust data Joining the GCP Network further strengthens that commitment. We look forward to contributing to a global community dedicated to raising the bar across clinical research.
Pharmidex now offers integrated in vivo CAR-T study support , combining robust in-life pharmacology with advanced f low cytometry –based cellular analysis. We support early-stage CAR-T and cell therapy programmes with translational data on efficacy, expansion, persistence and phenotype delivered through a single collaborative CRO partner. Let’s talk. 🌐 www.pharmidex.com
Pharmidex is pleased to share that Janette Dalay Robertson will be attending the Founders Growth Community Meeting and Networking x Innovate Cambridge event at The Glasshouse, Cambridge. Janette will be available to meet between 12:00–15:30 and looks forward to connecting with fellow attendees to explore new alliances in pre-clinical and clinical drug development. If you’re attending, let’s connect.
